Literature DB >> 35567605

Cardiac magnetic resonance T1 mapping for evaluating myocardial fibrosis in patients with type 2 diabetes mellitus: correlation with left ventricular longitudinal diastolic dysfunction.

Xi Liu1,2, Yue Gao1, Ying-Kun Guo3, Chun-Chao Xia1, Rui Shi1, Li Jiang1, Meng-Ting Shen1, Lin-Jun Xie3, Wan-Lin Peng1, Wen-Lei Qian1, Ming-Yan Deng4, Li-Ling Deng4, Yan Ren4, Zhi-Gang Yang5.   

Abstract

OBJECTIVES: We aimed to evaluate myocardial fibrosis using cardiac magnetic resonance (CMR) T1 mapping in type 2 diabetes mellitus (T2DM) patients and investigate the association between left ventricular (LV) subclinical myocardial dysfunction and myocardial fibrosis.
METHODS: The study included 37 short-term (≤ 5 years) and 44 longer-term (> 5 years) T2DM patients and 41 healthy controls. The LV global strain parameters and T1 mapping parameters were compared between the abovementioned three groups. The association of T1 mapping parameters with diabetes duration, in addition to other risk factors, was determined using multivariate linear regression analysis. The correlation between LV strain parameters and T1 mapping parameters was evaluated using Pearson's correlation.
RESULTS: The peak diastolic strain rates (PDSRs) were significantly lower in longer-term T2DM patients compared to those in healthy subjects and short-term T2DM patients (p < 0.05). The longitudinal peak systolic strain rate and peak strain were significantly lower in the longer-term T2DM compared with the short-term T2DM group (p < 0.05). The extracellular volumes (ECVs) were higher in both subgroups of T2DM patients compared with control subjects (all p < 0.05). Multivariate linear regression analysis showed that diabetes duration was independently associated with ECV (β = 0.413, p < 0.001) by taking covariates into account. Pearson's analysis showed that ECV was associated with longitudinal PDSR (r = - 0.441, p < 0.001).
CONCLUSION: T1 mapping could detect abnormal myocardial fibrosis early in patients with T2DM, which can cause a decline in the LV diastolic function. KEY POINTS: • CMR T1 mapping could detect abnormal myocardial fibrosis early in patients with T2DM. • The diabetes duration was independently associated with ECV. • Myocardial fibrosis can cause a decline in the LV diastolic function in T2DM patients.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Cardiovascular magnetic resonance; Myocardial fibrosis; Myocardial strain; Type 2 diabetes mellitus

Year:  2022        PMID: 35567605     DOI: 10.1007/s00330-022-08800-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  6 in total

Review 1.  Myocardial remodeling in hypertension.

Authors:  W Nadruz
Journal:  J Hum Hypertens       Date:  2014-05-08       Impact factor: 3.012

2.  Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR.

Authors:  Marianna Fontana; Steve K White; Sanjay M Banypersad; Daniel M Sado; Viviana Maestrini; Andrew S Flett; Stefan K Piechnik; Stefan Neubauer; Neil Roberts; James C Moon
Journal:  J Cardiovasc Magn Reson       Date:  2012-12-28       Impact factor: 5.364

3.  Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain.

Authors:  Yukun Cao; Wenjuan Zeng; Yue Cui; Xiangchuang Kong; Miao Wang; Jie Yu; Shan Zhang; Jing Song; Xu Yan; Andreas Greiser; Heshui Shi
Journal:  Cardiovasc Diabetol       Date:  2018-01-04       Impact factor: 9.951

4.  Histological validation of cardiovascular magnetic resonance T1 mapping markers of myocardial fibrosis in paediatric heart transplant recipients.

Authors:  Seiko Ide; Eugenie Riesenkampff; David A Chiasson; Anne I Dipchand; Paul F Kantor; Rajiv R Chaturvedi; Shi-Joon Yoo; Lars Grosse-Wortmann
Journal:  J Cardiovasc Magn Reson       Date:  2017-02-01       Impact factor: 5.364

5.  Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.

Authors:  Christophe Beauloye; Anne-Catherine Pouleur; Sibille Lejeune; Clotilde Roy; Alisson Slimani; Agnès Pasquet; David Vancraeynest; Jean-Louis Vanoverschelde; Bernhard L Gerber
Journal:  Cardiovasc Diabetol       Date:  2021-02-19       Impact factor: 9.951

6.  Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.

Authors:  Mario Luca Morieri; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Margherita Andretta; Mario Plebani; Gian Paolo Fadini; Saula Vigili de Kreutzenberg; Angelo Avogaro
Journal:  Cardiovasc Diabetol       Date:  2021-07-16       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.